Compared to the messenger RNA vaccines from Pfizer Inc./BioNTech SE and Moderna, Inc., Johnson & Johnson’s single-shot Ad26.COV2.S vaccine has fallen out of favor due to safety and manufacturing issues. But it could draw renewed interest with new data showing strong antibody responses among people receiving second shots of the vaccine, along with prior data showing activity against variants of concern.
Coronavirus Update: J&J Highlights Positive Booster Shot Data
Japan Withdraws Moderna Lots
Also, Moderna completed the submission of the BLA for mRNA-1273’s FDA approval, Pfizer starts a rolling submission for a booster shot and Brii Biosciences announced data for its two-antibody antiviral cocktail, and Japan withdraws selected lots of Moderna's vaccine over contamination worries.
More from COVID-19
More from Scrip
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.